Low vitamin D levels are associated with impaired virologic response to PEGIFN+RBV therapy in HIV-hepatitis C virus coinfected patients

AIDS

Volumn 27, Issue 2, 2013, Pages 227-232

  Mandorfer, Mattias ^a   Reiberger, Thomas ^a   Payer, Berit A ^a   Ferlitsch, Arnulf ^a   Breitenecker, Florian ^a   Aichelburg, Maximilian C ^b   Obermayer Pietsch, Barbara ^c   Rieger, Armin ^b   Trauner, Michael ^a   Peck Radosavljevic, Markus ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Universitatsklinik fur Dermatologie   (Austria)

^c MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

coinfection; hepatitis C virus; HIV; liver disease; virologic response; vitamin D deficiency

Indexed keywords

25 HYDROXYVITAMIN D; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG TREATMENT FAILURE; FEMALE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PRIORITY JOURNAL; RISK FACTOR; TREATMENT RESPONSE; VIRUS LOAD; VITAMIN BLOOD LEVEL;

ADULT; ANTIVIRAL AGENTS; COINFECTION; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV; HIV INFECTIONS; HUMANS; INTERFERON-ALPHA; MALE; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT PROTEINS; RIBAVIRIN; RISK FACTORS; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84872403200     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32835aa161     Document Type: Article

References (19)

1. Smith C, Sabin CA, Lundgren JD, Thiebaut R, Weber R, Law M, et al. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS 2010; 24:1537-1548.
2. Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006; 44:S6-S9.
3. R cell nadirs are at risk for faster fibrosis progression and portal hypertension. J Viral Hepat 2010; 17:400-409.
4. Graham CS, Baden LR, Yu E, Mrus JM, Carnie J, Heeren T, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001; 33:562-569.
5. Reiberger T, Obermeier M, Payer BA, Baumgarten A, Weitner L, Moll A, et al. Considerable under-treatment of chronic HCV infection in HIV patients despite acceptable sustained virolo-gical response rates in a real-life setting. Antivir Ther 2011; 16:815-824.
6. Mehta SH, Lucas GM, Mirel LB, Torbenson M, Higgins Y, Moore RD, et al. Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic. AIDS 2006; 20:2361-2369.
7. Lange CM, Bojunga J, Ramos-Lopez E, von Wagner M, Hassler A, Vermehren J, et al. Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy. J Hepatol 2011; 54:887-893.
8. Terrier B, Carrat F, Geri G, Pol S, Piroth L, Halfon P, et al. Low 25-OH vitamin D serum levels correlate with severe fibrosis in HIV-HCV co-infected patients with chronic hepatitis. J Hepatol 2011; 55:756-761.
9. Gal-Tanamy M, Bachmetov L, Ravid A, Koren R, Erman A, Tur-Kaspa R, et al. Vitamin D: an innate antiviral agent suppressing hepatitis C virus in human hepatocytes. Hepatology 2011; 54:1570-1579.
10. Bitetto D, Fabris C, Fornasiere E, Pipan C, Fumolo E, Cussigh A, et al. Vitamin D supplementation improves response to antiviral treatment for recurrent hepatitis C. Transplant 2011; 24:43-50.
11. Abu-Mouch S, Fireman Z, Jarchovsky J, Zeina AR, Assy N. Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naive patients. World J Gastroenterol 2011; 17:5184-5190.
12. Milazzo L, Mazzali C, Bestetti G, Longhi E, Foschi A, Viola A, et al. Liver-related factors associated with low vitamin D levels in HIV and HIV/HCV coinfected patients and comparison to general population. Curr HIV Res 2011; 9:186-193.
13. Payer BA, Reiberger T, Aberle J, Ferenci P, Holzmann H, Rieger A, et al. IL28B and interferon-gamma inducible protein 10 for prediction of rapid virologic response and sustained virologic response in HIV-HCV-coinfected patients. Eur J Clin Invest 2012; 42:599-606.
14. Theise ND. Liver biopsy assessment in chronic viral hepatitis: a personal, practical approach. Mod Pathol 2007; 20 (Suppl 1): S3-S14.
15. Medrano J, Neukam K, Rallon N, Rivero A, Resino S, Naggie S, et al. Modeling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfected with hepatitis C virus and HIV. Clin Infect Dis 2010; 51:1209-1216.
16. Neukam K, Camacho A, Caruz A, Rallon N, Torres-Cornejo A, Rockstroh JK, et al. Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load. J Hepatol 2012; 56:788-794.
17. Harris SS, Dawson-Hughes B. Seasonal changes in plasma 25-hydroxyvitamin D concentrations of young American black and white women. Am J Clin Nutr 1998; 67:1232-1236.
18. Petta S, Camma C, Scazzone C, Tripodo C, Di Marco V, Bono A, et al. Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C. Hepatology 2010; 51:1158-1167.
19. Bitetto D, Fattovich G, Fabris C, Ceriani E, Falleti E, Fornasiere E, et al. Complementary role of vitamin D deficiency and the interleukin-28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C. Hepatology 2011; 53:1118-1126.